MRSN MERSANA THERAPEUTICS INC revenue, earnings and financials

For the quarter ended September 30, 2025, MERSANA THERAPEUTICS INC reported revenue of $11.0M (down 12.6% from a year earlier), net income of −$7.55M and diluted EPS of −$1.51; over the last four quarters revenue was $33.2M and net income −$70.1M; for the fiscal year ended December 2024 revenue was $40.5M, up 9.9% on the year before.

MRSN annual revenue and earnings

• Fiscal year ended Dec 2024: revenue $40.5M, gross profit n/a, operating income n/a, net income −$69.2M (margin -170.9%), EPS −$0.56
• Fiscal year ended Dec 2023: revenue $36.9M, gross profit n/a, operating income n/a, net income −$172M (margin -465.8%), EPS −$1.48
• Fiscal year ended Dec 2022: revenue $26.6M, gross profit n/a, operating income n/a, net income −$204M (margin -768.3%), EPS −$2.18
• Fiscal year ended Dec 2021: revenue $43.0K, gross profit n/a, operating income n/a, net income −$170M (margin -395488.4%), EPS −$2.41

MRSN quarterly revenue and earnings

• Quarter ended Sep 30, 2025: revenue $11.0M (down 12.6% year over year), net income −$7.55M, EPS −$1.51
• Quarter ended Jun 30, 2025: revenue $3.06M (up 33.3% year over year), net income −$24.3M, EPS −$4.87
• Quarter ended Mar 31, 2025: revenue $2.75M (down 70.2% year over year), net income −$24.1M, EPS −$0.19
• Quarter ended Dec 31, 2024 (from the annual report): revenue $16.4M (up 52.9% year over year), net income −$14.1M, EPS $6.90
• Quarter ended Sep 30, 2024: revenue $12.6M (up 63.7% year over year), net income −$11.5M, EPS −$2.34
• Quarter ended Jun 30, 2024: revenue $2.29M (down 78.5% year over year), net income −$24.3M, EPS −$4.96
• Quarter ended Mar 31, 2024: revenue $9.25M (up 18.5% year over year), net income −$19.3M, EPS −$0.16
• Quarter ended Dec 31, 2023 (from the annual report): revenue $10.7M (down 27.1% year over year), net income −$19.5M, EPS −$0.14
• Quarter ended Sep 30, 2023: revenue $7.70M (up 38.1% year over year), net income −$41.7M, EPS −$0.35
• Quarter ended Jun 30, 2023: revenue $10.7M (up 148.7% year over year), net income −$54.3M, EPS −$0.47
• Quarter ended Mar 31, 2023: revenue $7.80M (up 283.2% year over year), net income −$56.2M, EPS −$0.52
• Quarter ended Dec 31, 2022 (from the annual report): revenue $14.7M (up 146780.0% year over year), net income −$44.9M, EPS −$0.43
• Quarter ended Sep 30, 2022: revenue $5.57M (up 50563.6% year over year), net income −$59.8M, EPS −$0.61
• Quarter ended Jun 30, 2022: revenue $4.28M (up 38845.5% year over year), net income −$52.2M, EPS −$0.55
• Quarter ended Mar 31, 2022: revenue $2.04M (up 18409.1% year over year), net income −$47.3M, EPS −$0.59
• Quarter ended Dec 31, 2021 (from the annual report): revenue $10.0K, net income −$49.0M, EPS −$0.69
• Quarter ended Sep 30, 2021: revenue $11.0K, net income −$45.5M, EPS −$0.63
• Quarter ended Jun 30, 2021: revenue $11.0K, net income −$40.9M, EPS −$0.59
• Quarter ended Mar 31, 2021: revenue $11.0K, net income −$34.7M, EPS −$0.50

MRSN cash flow, buybacks and dividends

• Fiscal year ended Dec 2024: operating cash flow −$82.3M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$169M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$49.4M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$140M, share buybacks n/a

MRSN balance sheet

• Sep 30, 2025: cash $56.4M, total assets $62.7M, total liabilities $122M, shareholders' equity −$59.5M, long-term debt $0
• Jun 30, 2025: cash $77.0M, total assets $84.6M, total liabilities $138M, shareholders' equity −$53.1M, long-term debt $0
• Mar 31, 2025: cash $102M, total assets $112M, total liabilities $143M, shareholders' equity −$30.9M, long-term debt $7.90M
• Dec 31, 2024: cash $108M, total assets $145M, total liabilities $154M, shareholders' equity −$9.51M, long-term debt $11.0M
• Sep 30, 2024: cash $78.9M, total assets $170M, total liabilities $168M, shareholders' equity $1.05M, long-term debt $14.0M
• Jun 30, 2024: cash $59.0M, total assets $179M, total liabilities $171M, shareholders' equity $8.43M, long-term debt $17.0M
• Mar 31, 2024: cash $75.2M, total assets $198M, total liabilities $170M, shareholders' equity $28.0M, long-term debt $19.8M
• Dec 31, 2023: cash $175M, total assets $226M, total liabilities $189M, shareholders' equity $36.9M, long-term debt $23.1M

What is MRSN's revenue?

MERSANA THERAPEUTICS INC reported $33.2M of revenue over its last four quarters, through September 30, 2025.

Is MRSN profitable?

No. MERSANA THERAPEUTICS INC lost $70.1M over the last four quarters.

What is MRSN's EPS?

Diluted earnings per share over the last four quarters were $0.33; −$1.51 in the latest quarter.

MRSN ownership and insider trades · All stocks